Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply by Authors.
Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Shore N, et al. Among authors: pieczonka c. J Urol. 2024 Dec;212(6):842-843. doi: 10.1097/JU.0000000000004221. Epub 2024 Sep 3. J Urol. 2024. PMID: 39226588 No abstract available.
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. Loeb S, et al. Among authors: pieczonka cm. JCO Precis Oncol. 2024 Mar;8:e2300552. doi: 10.1200/PO.23.00552. JCO Precis Oncol. 2024. PMID: 38452310 Free PMC article. Clinical Trial.
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF Jr, Venugopal B, Woo HH, Ramirez-Backhaus M, Tarazi J, Tang Y, Ganguli A, Haas GP, Shore ND. Freedland SJ, et al. Among authors: pieczonka cm. Future Oncol. 2024 Dec 12:1-14. doi: 10.1080/14796694.2024.2426425. Online ahead of print. Future Oncol. 2024. PMID: 39667819 Free article.
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Shore N, et al. Among authors: pieczonka c. J Urol. 2024 Dec;212(6):832-843. doi: 10.1097/JU.0000000000004190. Epub 2024 Aug 9. J Urol. 2024. PMID: 39121056
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: pieczonka c. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019. Oncologist. 2024. PMID: 38394384 Free PMC article. Clinical Trial.
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Freedland SJ, et al. Among authors: pieczonka cm. NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. NEJM Evid. 2023. PMID: 38320501 Clinical Trial.
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
Van Neste L, Henao R, Wojno KJ, Signes J, DeHart J, Busta A, Marriott E, Willing M, Argentini A, Hurley PM, Korman H, Hafron J, Putzi M, Pieczonka CM, Karsh LI, Morris DS, Kassis AI, Kantoff PW. Van Neste L, et al. Among authors: pieczonka cm. J Urol. 2024 Mar;211(3):415-425. doi: 10.1097/JU.0000000000003824. Epub 2023 Dec 26. J Urol. 2024. PMID: 38147400
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Shen J, et al. Among authors: pieczonka cm. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11. Br J Cancer. 2024. PMID: 37951974 Free PMC article.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Freedland SJ, et al. Among authors: pieczonka cm. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
41 results